Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

Mechanism of Action

Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects.

Typical Dosage (Research)

Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily.

Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications.

Side Effects & Risks

Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use.

Thyroid C-cell tumor warnings (contraindicated with personal/family history of MTC or MEN2). Risk of pancreatitis, gallbladder disease, and hypoglycemia when combined with insulin.

Who Uses Liraglutide

Those with type 2 diabetes, individuals seeking FDA-approved weight loss medication, patients who prefer daily dosing over weekly injections.